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1. Introduction  
Vitamin A (retinol) can be produced in the body by hydrolysis of retinyl esters or reduction 
of retinal. Liver and eggs, which are good animal sources of vitamin A, contain retinyl 
esters. Plant sources such as carrots and spinach contain pro-vitamin A carotenoids, which 
can be cleaved to retinal. Retinal, also called retinaldehyde, is interconvertible with retinol 
(Fig. 1). Retinal also serves as an intermediate in the irreversible production of all-trans-
retinoic acid (ATRA), which is considered the major biologically active derivative of vitamin 
A [Moise et al. 2007, Chambon 1996]. Another important derivative of vitamin A is the visual 
chromophore 11-cis-retinal [Wald 1968].  Binding of 11-cis-retinal to proteins called opsins is 
the chemical basis of vision. Vitamin A formed from retinyl esters or carotinoids in the 
normal diet, or ingested in fortified foods or dietary supplements, is stored in the liver and 
transported to tissues as a complex bound to retinol binding protein [Moise et al.  2007].  
 
CH2OH
Retinol (vitamin A)
CHO
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COOH
All-trans retinoic acid 
COOH
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Fig. 1. Formation of all-trans retinoic acid from vitamin A and structures of 9-cis retinoic 
acid and 11-cis-retinal.  
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Effects of retinoids are mediated primarily by two families of nuclear hormone receptors, 
retinoic acid receptors (RARs) and the retinoid X receptors (RXRs) [Bastein et al.  2004]. Each 
receptor family is made up of three isoforms (┙, ┚ and ┛), produced by separate genes. RARs 
can be activated by ATRA and the isomer 9-cis retinoic acid (9-cis RA), while RXRs are 
activated by 9-cis RA. RARs form heterodimers with RXRs and these heterodimers and RXR 
homodimers function as transcription factors, activating RAREs in the promoter regions of 
target genes. Most retinol signaling in cells is thought to be mediated by ATRA binding 
RAR in RAR/RXR heterodimers [Mic et al.  2003]. It is still not clear if 9-cis RA is formed 
physiologically in cells and what role this isomer may play as a specific ligand for RXR [Mic 
et al.  2003]. Activated retinoid receptors function as transcription factors, activating specific 
RA response elements (RAREs) for transcriptional regulation of target genes [Bastein et al. 
2004, Mic et al. 2003].  
Peroxisome proliferator-activated receptors (PPARs), ┙, ┚/├, and ┛, represent another group 
of nuclear hormone receptors that forms heterodimers with RXR. PPAR/RXR heterodimers 
also function as transcription factors, activating specific response elements of target genes 
[Mangelsdorf and Evans 1995, Bocher et al. 2002, Wilson et al. 2000]. Recent studies have 
indicated that ATRA not only can bind RARs, but can serve as a ligand for PPAR ┚/├ as 
well [Berry et al. 2007]. Channelling of ATRA to RARs or PPAR ┚/├ is suggested to depend 
on the intracellular binding proteins, RA binding protein II or keratinocyte fatty acid 
binding protein 5, which deliver ATRA to either RAR or PPAR ┚/├, respectively [Schug  et 
al. 2007].   
Vitamin A plays an essential role in numerous biological processes, including vision, 
cellular proliferation, differentiation, and apoptosis, organ development and function, and 
immunity [Moise et al. 2007, Mark et al. 2006, Mark et al. 2009]. Numerous malformations 
and impaired vision, growth, organ function, and reproduction have been noted with 
vitamin A deficiency.  Vitamin A is used in developing countries to help correct vitamin A 
deficiency [Moise et al. 2007]. Supplementation with vitamin A has had an enormous 
worldwide impact, saving countless lives, at minimal costs per patient.  There is also 
widespread use of vitamin A derivatives (retinoids) for treatment of various skin conditions, 
such as acne [Peck et al. 1979], and for different cancers, including acute promyelocytic 
leukemia (APL), Kaposi's sarcoma, head and neck squamous cell carcinoma, ovarian 
carcinoma, and neuroblastoma [Siddikuzzaman et al. 2010].  Use of retinoids has proved 
particularly useful for treatment of APL [Siddikuzzaman et al. 2010]. Pharmacological 
concentrations (10-7 - 10-6M) of ATRA block repression by a PML- RAR┙ fusion protein that 
interferes with normal RAR┙ transcriptional regulation in APL.   
Besides serving as an intermediate in retinoic acid formation, recent studies have shown that 
retinal (retinaldehyde) is present at biologically active concentrations in fat tissue, where it 
antagonizes PPAR-┛ activity, inhibits adipogenesis, and improves insulin sensitivity 
[Ziouzenkova et al. 2007].  These observations suggest that retinal may be an additional 
vitamin A derivative that plays an important role as a mediator of biological processes.  
Hypervitaminosis A in experimental animals has been linked to increased bone resorption, 
decreased bone mass, and increased fractures [Frankel et al. 1986, Hough et al. 1988, 
Johansson et al. 2002]. There are also case studies in humans showing that significantly 
increased intake of vitamin A increases bone resorption, causes hypercalcemia, and induces 
skeletal pain [Frame et al. 1974]. Supplementation of the diet with vitamins is a common 
occurrence in developed countries and there is presently debate over whether more modest 
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increases in vitamin A might promote skeletal abnormalities. Some studies have shown that 
increased vitamin A intake or elevated serum retinol levels [Michaelsson et al. 2003] are 
associated with an increased incidence of hip fracture or decreased bone mass [Melhaus et 
al. 1998, Feskanich et al. 2002, Promislow et al. 2002]; however, other studies have shown no 
deleterious effect on bone mass or fracture risk, and, in some instances, protection from 
bone loss because of increased vitamin A has been reported [Ribaya-Mercado and Blumberg 
2007, Caire-Juvera et al. 2009]. In studies where vitamin A analogues have been evaluated, 
decreases in bone mass have been reported following isotretinoin and acitretin usage in 
some instances, but a recent, large scale, case-control study has found no increased risk of 
fracture with these agents [Vestergaard et al. 2010]. 
2. Bone tissue 
Skeletal tissue is comprised primarily of either cortical (compact) or trabecular (cancellous) 
bone. In the adult, approximately 80% of skeletal mass is cortical bone and 20% trabecular 
bone. Cortical bone is found in the shafts of long bones and the outer surfaces of all other 
bones in the body. It is organized around blood vessels into cylinders of consolidated bone 
called osteons, or Haversian systems. Unlike trabecular bone, cortical bone does not contain 
bone marrow. Trabecular bone is characterized as a network of thin spicules of bone 
(“spongy bone”), which is found in the interior of vertebrae, flat bones in the skull, the 
pelvis and sacrum, and the distal and proximal parts of long bones. Both cortical and 
trabecular bone are important for bone strength.  In the adult skeleton, both types of bone 
are remodelled and modelled [Martin and Seeman 2008]. Modelling of bone is a process that 
changes the size and shape of bone either by bone resorption without subsequent bone 
formation, or bone formation without prior bone resorption. Remodelling of bone is the 
process by which old bone is replaced by new bone. It is initiated by bone resorption to 
remove damaged bone, followed by new bone formation in the area resorbed. Remodelling 
does not change the size or shape of the bones. Remodelling is more frequent in trabecular 
bone than in cortical bone, one of the reasons why a metabolic bone disease like 
postmenopausal osteoporosis affects primarily bones with proportionally increased 
amounts of trabecular bone, e.g. vertebrae, distal radius, and proximal femur. Remodelling 
is believed to be initiated by microcracks in the mineralized bone extracellular matrix and 
subsequent osteocytic apoptosis, which triggers osteoclast formation and resorption of the 
micro-damaged area [Martin and Seeman 2008]. The process causes release of “coupling 
factors” which attract and activate osteoblasts to form new bone under a canopy of bone 
lining cells [Martin and Sims 2005, Boyce et al. 2009, Martin et al. 2009]. When osteoblasts fill 
the resorption lacunae made by osteoclasts with new bone in the bone multicellular unit 
(BMU), remodelling is in balance and bone mass remains constant. This equilibrium 
involves bidirectional interactions between osteoclasts and osteoblasts to fine tune the 
balance between bone formation and bone resorption. 
The skeleton is a support structure that serves as a reservoir for calcium, phosphate, and 
numerous other minerals, protects vital organs such as brain, heart, lung, and bone marrow, 
and recently has been implicated in glucose- and energy metabolism [Confavreux et al. 
2009]. Three systemic hormones that play primary roles in calcium homeostasis and bone 
formation and resorption are parathyroid hormone (PTH), 1,25(OH)2-vitamin D3, and 
calcitonin.  PTH and 1,25(OH)2-vitamin D3 stimulate bone resorption when serum calcium 
decreases, whereas calcitonin inhibits bone resorption when serum calcium is increased. Sex 
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hormones also play important roles, with increased bone resorption and decreased bone 
formation occurring when levels of either estrogen or testosterone are decreased. Other 
agents known to play significant roles in bone turnover are the thyroid hormones, 
glucocorticoids, follicle stimulating hormone, and the retinoids. Interestingly, there is also a 
great deal of cross talk between bone cells and the immune system. This occurs during both 
normal physiological remodelling and in pathological inflammatory conditions involving 
bone, like rheumatoid arthritis and peridontitis [Takayanagi 2009]. 
3. Osteoclast differentiation 
Osteoclasts are multinucleated giant cells found on bone surfaces that stain for tartrate 
resistant acid phosphatise (TRAP). They are formed by fusion of mononucleated progenitor 
cells derived from hematopoetic myeloid stem cells, which also give rise to macrophages 
and dendritic cells. For fusion of osteoclast precursors to occur, they must be differentiated 
specifically along the osteoclastic lineage [Lorenzo and Horowitz 2008, Edwards and 
Mundy 2011]. Formation of osteoclasts is controlled by osteoblasts at the bone surface. Thus, 
osteoblasts are responsible for not only bone formation, but regulate bone resorption as 
well. In addition to hematopoetic cells, bone marrow also contains pluripotent mesenchymal 
cells which are able to support differentiation of osteoclasts [Askmyr et al. 2009]; however, 
mature osteoclasts do not form within bone marrow, but enter the circulation as 
mononucleated osteoclast progenitors and home to periosteal and endosteal tissues. The 
details of this attraction are not known at present, but stomal cell-derived factor-1 (SDF-1 or 
CXCL12) produced by osteoblasts and CXCR4 expressed by osteoclast progenitors may play 
important roles [Kollet et al. 2006]. To what extent the circulating osteoclast progenitor cells 
are primed in the bone marrow, or to what extent priming occurs in the periosteum and 
endosteum is also not known at present. Nor is it known if osteoclast formation in 
trabecular bone in the close vicinity of bone marrow is different from osteoclast formation in 
periosteal tissues, which are always some distance from bone marrow. Recently, one group 
has presented evidence for the existence of a unique periosteal macrophage – osteomac 
which not only can form osteoclasts, but is also able to control bone formation [Chang et al. 
2008]. Increasing evidence indicates that osteoclast formation does not follow a common 
pathway and that osteoclasts are different in different parts of the skeleton [Everts et al. 
2009, Henriksen et al.  2011].  
Crude bone marrow cultures, or co-cultures of periosteal osteoblasts and purified osteoclast 
progenitors from either bone marrow or spleens, have shown that osteoclast formation 
requires close physical contact of progenitor cells with either stromal cells in the bone marrow 
or osteoblasts. Molecularly, it has been found that macrophage colony-stimulating factor (M-
CSF) and receptor activator of nuclear factor B ligand (RANKL) are two products of stromal 
cells/osteoblasts that play key roles in regulating osteoclast formation. M-CSF supports 
progenitor cell proliferation and survival, and RANKL is responsible for progenitor 
differentiation to osteoclasts, rather than to macrophages or dendritic cells [Takayanagi 2009, 
Lorenzo and Horowitz 2008, Nakashima and Takayanagi 2009]. RANKL, which is a member 
of the TNF superfamily, functions by binding to RANK on osteoclast progenitor cells. 
Osteoprotegerin (OPG), a soluble protein released from stromal cells/osteoblasts, is another 
key factor regulating osteoclastogenesis. OPG functions as a decoy receptor for RANKL, 
blocking interaction between RANKL and RANK. The expression of RANKL is thought to be 
restricted to a relatively small number of cells: bone marrow stromal cells, osteoblasts, 
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periodontal ligament cells, synovial fibroblasts, T-, B- and NK-cells, while OPG appears to be 
ubiquitously expressed. It is the relative expression of RANKL and OPG which determines 
whether osteoclast formation will take place. Enhancement of the RANKL/OPG ratio in 
stromal cells or osteoblasts by hormones and cytokines causes stimulation of bone resorption.  
Following RANKL binding to trimeric RANK, association of the cytoplasmic tail of RANK 
with TNF receptor-associated factor 6 (TRAF 6) leads to activation of several kinases, 
including IKK, MAPKs such as p38 and JNK, and PI3K (Fig. 2). Subsequently, transcription 
factors such as NF-B, AP-1, MITF, NFATc1 and Akt are activated. Within the NF-B family 
of transcription factors, p50 and p52 seem to be the most important subunits [Boyce et al. 
2010]. RANK signaling leads to induction and activation of c-fos, which functions as a 
component of the transcription factor, activator protein-1 (AP-1). Mice with double 
knockouts of p50/p52 or with deletion of the c-Fos gene lack osteoclasts and exhibit 
osteopetrosis. The induction of the master transcription factor for osteoclastogenesis, 
NFATc1, is dependent on NF-B and c-fos signaling by RANK [Negishi-Koga and 
Takayanagi 2009]. In cooperation with RANK, immunoglobulin-like receptors associated 
with adaptor proteins harboring the immunoreceptor tyrosine-based activation motif 
(ITAM) activate phospholipase C┛, calcium signaling, and the formation of calcineurin 
required for activation of NFATc1 [Nemeth et al. 2011]. The activation of specific genes 
necessary for osteoclastogenesis and osteoclast function is regulated by NFATc1 cooperating 
with other transcription factors, such as AP-1, CREB, PU.1, and MITF. Important osteoclast 
genes include those encoding calcitonin receptor and TRAP, which serve as osteoclast 
markers, cathepsin K, which is involved in breakdown of bone matrix collagen, Atp6i and 
chloride chanel-7, involved in acidification and dissolution of bone mineral crystals, and the 
integrins v and 3, which are important for attachments of osteoclasts to bone surfaces. 
 
RANKL
RANK
TRAF6
Immunogl-like
receptors
FcR DAP12
PI3K MAPK IKK Calcineurin
NFB
(p50/p52)
AP-1
(c-Fos/c-Jun)
MITF PU.1 NFATc1 Akt MafB IRF8
proliferation, survival, differentiation and fusion of osteoclast progenitors
Rank, Oscar; Trap, Calctr, cathepsin K; Atp6i, v, 3
CELL
MEMBRANE
M-CSF
c-Fms
Figure 2  
Fig. 2. Osteoclastogenic pathways, transcription factors, and genes stimulated by M-CSF and 
RANKL.   
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4. Retinoids and bone resorption in vitro 
The effect of vitamin A on bone resorption has been studied the most thoroughly in rodent 
models. It has been known since the 1920´s that excess vitamin A has effects on the skeleton. 
In classical experiments in 1952 employing cultured fetal mouse limb bones, Dame Honor 
Fell showed that hypervitaminosis A stimulated osteoclast formation and bone resorption 
[Fell and Mellanby 1952]. Thirteen years later, Larry Raisz showed that vitamin A could 
stimulate bone resorption in organ cultures of fetal rat long bones [Raisz 1965]. Since those 
early experimental reports, there have been additional studies in organ cultures of fetal rat 
long bones [Scheven and Hamilton 1990], fetal rat calvariae [Delaissé et al. 1988] and 
calvarial bones from both fetal [Delaissé et al. 1988] and newborn [Raisz et al. 1977, Togari et 
al. 1991, Kindmark et al. 95, Conaway et al. 1997] mice confirming the osteoclastogenic effects 
of vitamin A and derivatives. An investigation indicating that ATRA increases mRNA 
expression of RANKL in primary human osteoblast-like cultures and decreases mRNA 
expression and protein formation of OPG in human MG-63 osteosarcoma cells [Jacobson et 
al. 2004] led to the suggestion that bone resorption stimulated by the retinoid is due to an 
increased RANKL/OPG ratio; however, until recently, there had been no data from bone or 
bone culture systems showing how vitamin A or derivatives stimulated bone resorption. In 
a recent investigation, we have reported that stimulation of osteoclastogenesis and bone 
resorption by retinoids in neonatal mouse calvarial bone is due to increased RANKL mRNA 
and protein expression. Supporting evidence for the role of RANKL was the observation 
that exogenous OPG administration blocked retinoid induced calvarial bone resorption 
[Henning et al. 2011].  
Resorption in the bone organ culture systems depends on increased osteoclast formation 
and/or enhanced osteoclast activity. Attempts to elucidate effects of vitamin A on mature 
osteoclasts have generated conflicting results. It has been reported that bone resorbing 
activity of rabbit osteoclasts incubated on dentine slices is enhanced by ATRA [Saneshige et 
al. 1995]. Additionally, the vitamin A derivative isotretinonin has been observed to increase 
activity of rat osteoclasts incubated on cortical bone slices [Lakkakorpi and Väänänen 1991]. 
In contrast, bone resorbing activity of embryonic chicken osteoclasts on either bovine 
cortical bone or sperm whale dentine has been reported to be decreased by ATRA [O´Neill 
et al. 1992]. Furthermore, degradation of bone particles incubated with chicken osteoclasts is 
said to be enhanced by retinol and ATRA [Oreffo et al. 1988], which differs from 
experiments using osteoclast-like cell lines from human giant cell bone tumors, where 
Colucci et al. have found that ATRA inhibits degradation of bone matrix in rat bone particles 
[Colucci et al. 1996].  
Evaluations of the effects of vitamin A on osteoclast formation have also generated 
conflicting data. In human bone marrow cultures, ATRA has been reported to stimulate 
formation of osteoclast-like multinucleated cells that are incapable of resorbing bone 
[Thavarajah et al. 1991]. Formation of multinucleated osteoclasts unable to resorb bone has 
also been reported following ATRA treatment of bone marrow cultures from egg laying 
hens [Chiba et al. 1996]. Scheven and Hamilton [1990] found no effect of ATRA on osteoclast 
formation in rat bone marrow cultures; however, when Hata et al. [1992] stimulated 
osteoclast formation in rat bone marrow cultures with 1,25(OH)2-vitamin D3, they found 
inhibition with ATRA. Using an acyclic retinoid, geranylgeranoic acid, Wang et al. [2002] 
also found that osteoclast formation in mouse bone marrow cultures stimulated by 
1,25(OH)2-vitamin D3 was inhibited. Inhibition by the retinoid was most likely due to 
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inhibition of osteoclast progenitor cells, since inhibition of osteoclast formation by 
geranylgeranoic acid was also observed in mouse bone marrow macrophage (BMM) 
cultures stimulated by RANKL. In agreement with these latter observations, we have 
recently shown that ATRA, as well as 9-cis retinoic acid, inhibit osteoclast formation in 
mouse bone marrow cell cultures stimulated with either 1,25(OH)2-vitamin D3 or PTH 
[Conaway et al. 2009], an effect associated with decreased expression of the osteoclast genes 
Calcr, Acp5, and Catsk, which code for the calcitonin receptor, TRAP, and cathepsin K, 
respectively. ATRA did not affect 1, 25(OH)2-vitamin D3 stimulated mRNA expression of 
Rankl, nor did the retinoid affect the decrease of Opg expression induced by 1,25(OH)2-
vitamin D3, suggesting that the inhibitory effect was at the level of osteoclast progenitors 
rather than stromal cells. Osteoclast formation in both crude bone marrow cultures and 
spleen cell cultures stimulated by RANKL was also inhibited by ATRA and 9-cis retinoic 
acid. Moreover, osteoclast formation stimulated by RANKL in highly purified mouse BMM 
cultures was inhibited by ATRA and 9-cis retinoic acid, providing good evidence that the 
retinoids inhibited osteoclastogenesis by directly affecting osteoclast progenitor cells. 
Inhibition of osteoclast progenitor cell differentiation by ATRA was due to inhibition of AP-1 
and Nfatc1 pathways, but did not involve the NF-B pathway [Conaway et al. 2009]. ATRA 
inhibited mRNA and protein expression of the transcription factors c-Fos and Nfatc1 induced 
by RANKL. RANKL also enhanced the mRNA expression of Fra-1, Fra-2 and JunB in mouse 
BMM, but ATRA inhibited only Fra-2. The decrease of the macrophage transcription factor 
MafB caused by RANKL during osteoclastogenesis was blunted by ATRA, suggesting that 
ATRA arrested precursor cells at the macrophage stage. In agreement with these observations, 
it has been observed that ATRA inhibits Nfatc1 expression, translocation, and DNA-binding in 
RAW264.7 cells and mouse BMM [Balkan et al. 2011]. 
Mouse BMM express RAR and RAR, but little RAR. By use of different agonists and 
antagonists, it was demonstrated that ATRA induced inhibition of RANKL stimulated 
osteoclast formation in BMM was mediated by RAR [Conaway et al. 2009]. As discussed 
above, ATRA can also serve as a ligand for PPAR/. However, ligands specific for this 
receptor did not mimic the inhibitory effect of ATRA. 
Effects of retinoids on osteoclast formation have also been studied using osteoclast 
progenitor cells isolated from peripheral blood.  Woods et al. [1995] found that monocytes 
from chicken peripheral blood spontaneously formed giant cells with osteoclast like features 
and that this process was inhibited by ATRA. Recently, it was shown that ATRA inhibited 
osteoclast formation in RANKL stimulated cultures of human CD14+ monocytes from 
peripheral blood [Hu et al. 2010]. In agreement with observations in RANKL stimulated 
mouse BMM, inhibition of osteoclast formation in human CD14+ cells was associated with 
decreased mRNA expression of osteoclastic genes such as ACP5 and CATSK, and the 
transcription factor NFATc1, indicating that retinoids inhibit osteoclast formation by 
inhibiting osteoclast differentiation rather than fusion of differentiated progenitor cells. The 
authors attributed the inhibition to decreased expression of RANK mRNA and protein; 
however, it remains to be shown if this is the primary event. 
5. Retinoids and bone resorption in vivo 
In short term in vivo studies where rodents were treated with increased concentrations of 
retinoids (ATRA or Ro 13-6298), it has been reported that thinning of cortical bone due to 
significant stimulation of periosteal resorption occurs at the same time that cancellous bone 
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resorption is inhibited [Kneissel et al. 2005]. Furthermore, in a recent one week study where 
rats were fed increased vitamin A, increased cortical osteoclasts and cortical bone thinning 
were also observed; however, in these animals, endosteal osteoclasts disappeared because of 
impaired endosteal/marrow blood flow, which resulted in hypoxia and pathological 
endosteal mineralization [Lind et al. 2011]. This resulted in thinner, more brittle bones with 
little apparent affect on bone mass. Vitamin A and retinoids stimulate resorption in cultured 
fetal mouse and rat limb bones [Fell and Mellanby 1952, Raisz 1965, Scheven et al. 1990], but 
these studies are normally based on calcium release to medium and do not distinguish 
between cortical and cancellous bone breakdown. On the other hand, calvarial bone is 
considered to be a good model for periosteal resorption of cortical bone and it is established 
that vitamin A and ATRA are effective stimulators of osteoclastogenesis and bone 
resorption in calvarial bone [Raisz et al. 1977, Togari et al. 1991, Kindmark et al. 1995, 
Conaway et al. 1997]. As stated previously, retinoids are also good inhibitors of 
osteoclastogenesis in mouse bone marrow cell and BMM cultures. Thus, when comparing 
results of in vitro and in vivo experimental studies attempting to access the effects of 
increased vitamin A, it appears there may be good agreement regarding cortical osteoclast 
formation and function stimulated by vitamin A. In contrast, it seems a continuum of effects 
may occur in the endosteum, with increased vitamin A inhibiting endosteal osteoclast 
formation and function, and impaired blood flow and hypoxia promoting osteoclast death.  
6. Conclusion 
In developed countries, the diet is often supplemented with vitamin A and there is presently 
controversy over whether increased intake of vitamin A might promote skeletal fragility 
[Michaelsson et al. 2003, Melhaus et al. 1998, Feskanich et al. 2002, Promislow et al. 2002, 
Ribaya-Mercado and Blumberg 2007, Caire-Juvera et al. 2009]. If cortical bone thinning and 
suppression of osteoclastogenesis in cancellous bone play prominent roles in fracture 
incidence in humans following increased intake of vitamin A, this would be substantially 
different from conditions such as postmenopausal osteoporosis and glucocorticoid excess, 
where the increased incidence of fracture is due primarily to cancellous bone loss. These 
different paradigms for bone fragility may help explain some of the differing outcomes in 
studies evaluating vitamin A intake and fracture risk. It also seems possible that a duality of 
retinoid action on osteoclast precursors in cortical and cancellous bone might be manifest as 
different degrees of cortical resorption and cancellous inhibition, depending on other 
systemic and environmental factors. This would also affect bone mass and fracture risk, as 
would the development of hypoxia and death of endosteal osteoclasts. Our improving  
understanding of vitamin A action in bone cells is not only promising to be extremely 
valuable for future experimentation, but appears to warrant new evaluations of bone mass 
and fracture risk in patients with increased intake of vitamin A as well. 
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